- Blood related cancers such leukemia (current)
- Current active treatment for cancer – including chemotherapy, radiotherapy, and/or hormonal therapy
- Recipients of a solid organ transplant with immunosuppressive therapy
- Stem-cell transplant recipients or chimeric antigen receptor T-cell (CAR-T) therapy within 2 years of transplantation.
- Multiple immunosuppressants where the cumulative effect is considered to be severely immunosuppressive
- Primary immunodeficiency conditions – including combined immunodeficiency and syndromes, major antibody deficiency (e.g., common variable immune deficiency (CVID) or agammaglobulinemia), defects of innate immunity (including phagocytic cells), defects of immune regulation, complement deficiencies and phenocopies of primary immunodeficiencies.
- HIV with CD4 counts <250/μL or those with a higher CD4 count unable to be established on effective anti-retroviral therapy
- Long term renal dialysis
Anyone taking the following immunosuppressive therapies (now or at the time of dose 1 and 2):
- Mycophenolate
- Methotrexate (10mg per week or more)
- Leflunomide
- Azathioprine ≥0.5mg/kg/day
- 6-mercaptopurine
- Cyclophosphamide
- Cyclosporin
- Tacrolimus
- High dose corticosteroid treatment equivalent to >20mg/day of prednisone for ≥14 days in a month
- Abatacept
- Eculizumab
- Alemtuzumab
- Fingolimod
